8-K: Inozyme Pharma Announces Positive Interim Data for INZ-701 in Rare Disease Trials

Inozyme Pharma reports positive interim results for INZ-701 in infants and young children with ENPP1 Deficiency, along with key program updates including completed enrollment in a pivotal trial and regulatory guidance for another.

Summary

• Inozyme Pharma has announced positive interim data from its ENERGY 1 trial and Expanded Access Program (EAP) for INZ-701, a treatment for ENPP1 Deficiency in infants and young children.
• The data shows an 80% survival rate beyond the first year for treated infants, compared to a historical rate of approximately 50%.
• The study also observed substantial reductions or stabilization of arterial calcifications in all surviving patients, with some experiencing complete resolution.
• Improvements or stabilization in heart function, specifically left ventricular ejection fraction, were noted in all surviving patients.
• There was no radiographic evidence of rickets in patients evaluated beyond one year of age, supported by stable or increased serum phosphate levels.
• INZ-701 was well-tolerated, with only mild injection site reactions reported as treatment-related adverse events.
• Enrollment is complete in the ENERGY 3 pivotal trial for patients with ENPP1 Deficiency aged 1 to 13 years, with topline data expected in early 2026.
• The company has received regulatory guidance for its planned ASPIRE pivotal trial in children with ABCC6 Deficiency, with a target of enrolling approximately 70 patients.
• The ASPIRE trial is expected to begin in early 2026, pending regulatory review and financial resources.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data, particularly the improved survival rate and reduction in arterial calcifications. The completion of enrollment in one trial and regulatory support for another are also strong positives. However, the need for additional capital and the presence of ADAs in some patients temper the overall sentiment slightly.

Positives

• The survival rate of infants treated with INZ-701 is significantly higher than the historical rate, with 80% surviving beyond the first year compared to 50%.
• INZ-701 has shown effectiveness in reducing or stabilizing arterial calcifications, a key driver of morbidity and mortality in GACI.
• The treatment has demonstrated improvements in heart function, as evidenced by stabilization or improvement in left ventricular ejection fraction.
• INZ-701 appears to prevent the development of rickets in at-risk children, supported by stable or increased serum phosphate levels.
• The safety profile of INZ-701 is favorable, with only mild injection site reactions reported as treatment-related adverse events.
• Enrollment completion in the ENERGY 3 trial indicates progress in the development of INZ-701 for ENPP1 Deficiency.
• Preliminary regulatory support for the ASPIRE trial suggests a clear path forward for INZ-701 in treating ABCC6 Deficiency.

Negatives

• Some infants in the ENERGY 1 trial and EAP developed higher anti-drug antibody (ADA) levels, which significantly affected pharmacokinetics (PK) and pharmacodynamics (PD).
• While ADAs were not associated with adverse events, they did impact drug exposure and PPi levels in some infants.
• The company notes that the estimated cash, cash equivalents, and short-term investments of approximately $113.1 million as of December 31, 2024, are preliminary and unaudited.
• The actual financial results may differ materially from the preliminary estimated financial information.

Risks

• The company's ability to conduct ongoing clinical trials, enroll patients, and obtain regulatory approvals are subject to risks and uncertainties.
• There is a risk that positive results from early-stage trials may not be replicated in later clinical trials.
• The company may face challenges in advancing product candidates under anticipated timelines.
• The company needs to raise substantial additional capital to achieve its business objectives.
• The company is subject to risks associated with managing expenses and complying with loan agreements.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates completing the one-year dosing period for all patients in the ENERGY 3 trial by January 2026, with topline data expected in early 2026. The company also aims to initiate the ASPIRE trial in early 2026, pending regulatory review and financial resources.

Management Comments

• Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma, stated that the encouraging outcomes in infants and young children, combined with previous adult data, provide strong support for the potential impact of INZ-701 on rickets.
• Matt Winton, Ph.D., Senior Vice President and COO of Inozyme Pharma, emphasized the company's commitment to the patient community and addressing unmet needs across all populations.

Industry Context

This announcement is significant in the context of rare disease drug development, as it highlights positive clinical results for a potential treatment for ENPP1 and ABCC6 Deficiencies, conditions with no currently approved therapies. The progress in clinical trials and regulatory engagement positions Inozyme as a key player in this space.

Comparison to Industry Standards

• The 80% survival rate in infants treated with INZ-701 is a significant improvement compared to the historical survival rate of approximately 50% for GACI, a severe manifestation of ENPP1 Deficiency.
• The observed reductions in arterial calcifications and improvements in heart function are notable outcomes, as these are key indicators of disease progression and severity in ENPP1 Deficiency.
• The completion of enrollment in the ENERGY 3 trial and the preliminary regulatory support for the ASPIRE trial are positive milestones, indicating that Inozyme is progressing well in its clinical development program.
• The company's approach of targeting the PPi-Adenosine Pathway is innovative and could potentially address multiple diseases caused by deficiencies in these molecules, setting it apart from other companies in the rare disease space.
• Companies like Ultragenyx Pharmaceutical and BioMarin Pharmaceutical also focus on rare disease treatments, but Inozyme's specific focus on the PPi-Adenosine Pathway and its clinical results in ENPP1 and ABCC6 Deficiencies are unique.

Stakeholder Impact

• Shareholders will likely view the positive clinical data and trial progress favorably.
• Patients and their families will be encouraged by the potential of INZ-701 to treat these rare and severe conditions.
• Employees will be motivated by the progress in clinical development and the potential to bring a new therapy to market.
• The company's progress may attract potential partners and investors.

Next Steps

• The company plans to complete the one-year dosing period for all patients in the ENERGY 3 trial by January 2026.
• Topline data from the ENERGY 3 trial is expected in early 2026.
• The company will continue regulatory engagement to finalize the trial protocol for the ASPIRE trial.
• The company aims to initiate the ASPIRE trial in early 2026, pending regulatory review and financial resources.

Key Dates

Keywords

INZ-701, ENPP1 Deficiency, ABCC6 Deficiency, GACI, Arterial Calcification, Rickets, Clinical Trial, Rare Disease, Pivotal Trial, Regulatory Approval, Biopharmaceutical